Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Sjöwall, Johanna ^a   Ledel, Anna ^b   Ernerudh, Jan ^b   Ekerfelt, Christina ^b   Forsberg, Pia ^a,b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cross over; Cytokines; Doxycycline; Immunomodulation; Neuroborreliosis; Post treatment; Randomized; Symptoms

Indexed keywords

CEFTRIAXONE; CYTOKINE; DOXYCYCLINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RESPONSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FACE ERYTHEMA; FEMALE; HUMAN; LYME DISEASE; MALE; NAUSEA; NEUROLOGIC EXAMINATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYME NEUROBORRELIOSIS; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84870185521     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-186     Document Type: Article

References (63)

1. Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringer A, Elmrud H, Carlsson M, Runehagen A, Svanborg C, Norrby R. An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 1995, 333(20):1319-1327. 10.1056/NEJM199511163332004, 7566023.
2. Stanek G, Strle F. Lyme borreliosis: a European perspective on diagnosis and clinical management. Curr Opin Infect Dis 2009, 22(5):450-454. 10.1097/QCO.0b013e32832ee880, 19571749.
3. Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis 1999, 28(3):569-574. 10.1086/515145, 10194080.
4. Oksi J, Nikoskelainen J, Hiekkanen H, Lauhio A, Peltomaa M, Pitkaranta A, Nyman D, Granlund H, Carlsson SA, Seppala I, et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis 2007, 26(8):571-581. 10.1007/s10096-007-0340-2, 17587070.
5. Vrethem M, Hellblom L, Widlund M, Ahl M, Danielsson O, Ernerudh J, Forsberg P. Chronic symptoms are common in patients with neuroborreliosis - a questionnaire follow-up study. Acta Neurol Scand 2002, 106(4):205-208. 10.1034/j.1600-0404.2002.01358.x, 12225315.
6. Berglund J, Stjernberg L, Ornstein K, Tykesson-Joelsson K, Walter H. 5-y Follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002, 34(6):421-425. 10.1080/00365540110080421, 12160168.
7. Treib J, Fernandez A, Haass A, Grauer MT, Holzer G, Woessner R. Clinical and serologic follow-up in patients with neuroborreliosis. Neurology 1998, 51(5):1489-1491. 10.1212/WNL.51.5.1489, 9818893.
8. Picha D, Moravcova L, Lasikova S, Holeckova D, Maresova V. Symptoms of post-Lyme syndrome in long-term outcome of patients with neuroborreliosis. Scand J Infect Dis 2006, 38(8):747-748. 10.1080/00365540600810000, 16857637.
9. Henningsson AJ, Malmvall BE, Ernerudh J, Matussek A, Forsberg P. Neuroborreliosis - an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden. Clin Microbiol Infect 2010, 16(8):1245-1251.
10. Steiner I. Treating post Lyme disease: trying to solve one equation with too many unknowns. Neurology 2003, 60(12):1888-1889. 10.1212/01.WNL.0000077046.67754.60, 12821728.
11. Aalto A, Sjowall J, Davidsson L, Forsberg P, Smedby O. Brain magnetic resonance imaging does not contribute to the diagnosis of chronic neuroborreliosis. Acta Radiol 2007, 48(7):755-762. 10.1080/02841850701367903, 17729007.
12. Morgen K, Martin R, Stone RD, Grafman J, Kadom N, McFarland HF, Marques A. FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome. Neurology 2001, 57(11):1980-1985. 10.1212/WNL.57.11.1980, 11739813.
13. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, Dattwyler R, Chandler B. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003, 60(12):1923-1930. 10.1212/01.WNL.0000071227.23769.9E, 12821734.
14. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001, 345(2):85-92. 10.1056/NEJM200107123450202, 11450676.
15. Feder HM, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP, Agger WA, Artsob H, Auwaerter P, Dumler JS, et al. A critical appraisal of "chronic Lyme disease". N Engl J Med 2007, 357(14):1422-1430. 10.1056/NEJMra072023, 17914043.
16. Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis 2002, 2(4):255-263. 10.1089/153036602321653842, 12804167.
17. Hunfeld KP, Kraiczy P, Kekoukh E, Schafer V, Brade V. Standardized in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents-possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol 2002, 291(Suppl 33):125-137.
18. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis 2010, 37(3):534-541. 10.1016/j.nbd.2009.11.016, 19944760.
19. Pachner AR, Amemiya K, Delaney E, O'Neill T, Hughes CA, Zhang WF. Interleukin-6 is expressed at high levels in the CNS in Lyme neuroborreliosis. Neurology 1997, 49(1):147-152. 10.1212/WNL.49.1.147, 9222183.
20. Garcia-Monco JC, Benach JL. Mechanisms of injury in Lyme neuroborreliosis. Semin Neurol 1997, 17(1):57-62. 10.1055/s-2008-1040914, 9166961.
21. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009, 33(3):355-366. 10.1016/j.neubiorev.2008.10.005, 18996146.
22. Teeling JL, Perry VH. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 2009, 158(3):1062-1073. 10.1016/j.neuroscience.2008.07.031, 18706982.
23. Oksi J, Savolainen J, Pene J, Bousquet J, Laippala P, Viljanen MK. Decreased interleukin-4 and increased gamma interferon production by peripheral blood mononuclear cells of patients with Lyme borreliosis. Infect Immun 1996, 64(9):3620-3623. 174272, 8751908.
24. Ekerfelt C, Forsberg P, Svenvik M, Roberg M, Bergstrom S, Ernerudh J. Asymptomatic Borrelia-seropositive individuals display the same incidence of Borrelia-specific interferon-gamma (IFN-gamma)-secreting cells in blood as patients with clinical Borrelia infection. Clin Exp Immunol 1999, 115(3):498-502. 10.1046/j.1365-2249.1999.00840.x, 1905261, 10193424.
25. Jarefors S, Janefjord CK, Forsberg P, Jenmalm MC, Ekerfelt C. Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals. Clin Exp Immunol 2007, 147(1):18-27. 1810439, 17177959.
26. Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergstrom S, Forsberg P, Ernerudh J. Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome. J Infect Dis 2004, 189(10):1881-1891. 10.1086/382893, 15122525.
27. Henningsson AJ, Tjernberg I, Malmvall BE, Forsberg P, Ernerudh J. Indications of Th1 and Th17 responses in cerebrospinal fluid from patients with Lyme neuroborreliosis: a large retrospective study. J Neuroinflammation 2011, 8:36. 10.1186/1742-2094-8-36, 3108302, 21507218.
28. Nordberg M, Forsberg P, Johansson A, Nyman D, Jansson C, Ernerudh J, Ekerfelt C. Cytotoxic mechanisms may play a role in the local immune response in the central nervous system in neuroborreliosis. J Neuroimmunol 2011, 232(1-2):186-193.
29. Bannwarth B. Antimicrobial effects of antiinflammatory drugs, antiinflammatory effects of antimicrobial drugs. Rev Rhum Engl Ed 1999, 66(1 Suppl):73S-76S.
30. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and Minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis 2009, 199(9):1379-1388. 10.1086/597807, 19301981.
31. Lai AY, Todd KG. Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. Glia 2006, 53(8):809-816. 10.1002/glia.20335, 16541436.
32. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007, 69(14):1404-1410. 10.1212/01.wnl.0000277487.04281.db, 17909152.
33. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, Patry DG, Bell RB, Yong VW. The clinical response to Minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007, 13(4):517-526.
34. Stanek G, O''Connell S, Cimmino M, Aberer E, Kristoferitsch W, Granstrom M, Guy E, Gray J. European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 1996, 108(23):741-747.
35. Sullivan M, Karlsson J, Taft C, Ware J. Svensk manual och tolkningsguide, 2nd edn 2002, Göteborg: SF-36 Hälsoenkät.
36. Ware J, Kosinski M, Keller S. SF-36® Physical and Mental Summary Scales 1994, Boston, MA: The Health Institute: A User's Manual.
37. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968, 97:77-89.
38. Forsberg P, Ernerudh J, Ekerfelt C, Roberg M, Vrethem M, Bergstrom S. The outer surface proteins of Lyme disease borrelia spirochetes stimulate T cells to secrete interferon-gamma (IFN-gamma): diagnostic and pathogenic implications. Clin Exp Immunol 1995, 101(3):453-460. 1553228, 7664493.
39. Ekerfelt C, Ernerudh J, Bunikis J, Vrethem M, Aagesen J, Roberg M, Bergstrom S, Forsberg P. Compartmentalization of antigen specific cytokine responses to the central nervous system in CNS borreliosis: secretion of IFN-gamma predominates over IL-4 secretion in response to outer surface proteins of Lyme disease Borrelia spirochetes. J Neuroimmunol 1997, 79(2):155-162. 10.1016/S0165-5728(97)00118-5, 9394788.
40. Widhe M, Skogman BH, Jarefors S, Eknefelt M, Enestrom G, Nordwall M, Ekerfelt C, Croner S, Bergstrom S, Forsberg P, et al. Up-regulation of Borrelia-specific IL-4- and IFN-gamma-secreting cells in cerebrospinal fluid from children with Lyme neuroborreliosis. Int Immunol 2005, 17(10):1283-1291. 10.1093/intimm/dxh304, 16176932.
41. Widhe M, Ekerfelt C, Jarefors S, Skogman BH, Peterson EM, Bergstrom S, Forsberg P, Ernerudh J. T-cell epitope mapping of the Borrelia garinii outer surface protein A in Lyme neuroborreliosis. Scand J Immunol 2009, 70(2):141-148. 10.1111/j.1365-3083.2009.02285.x, 19630920.
42. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43(9):1089-1134. 10.1086/508667, 17029130.
43. Behandling av och profylax mot fästingöverförda infektioner - behandlingsrekommendationer http://www.lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/fastingar2.pdf.
44. Sullivan MKJ, Taft C, Ware JE. SF-36 Hälsoenkät-Svensk manual och tolkningsguide, 2 edn 2002, Gothenburg: SF-36 Hälsoenkät-Svensk manual och tolkningsguide, 2 edn.
45. Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 2005, 34(6):1340-1345. 10.1093/ije/dyi129, 16040645.
46. Pfister HW, Rupprecht TA. Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. Int J Med Microbiol 2006, 296(Suppl 40):11-16.
47. Bujak DI, Weinstein A, Dornbush RL. Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol 1996, 23(8):1392-1397.
48. Roelen CA, Koopmans PC, Groothoff JW. Subjective health complaints in relation to sickness absence. Work 2010, 37(1):15-21.
49. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED. Long-term outcomes of persons with Lyme disease. JAMA 2000, 283(5):609-616. 10.1001/jama.283.5.609, 10665700.
50. Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. Am J Med 2010, 123(1):79-86. 10.1016/j.amjmed.2009.05.011, 20102996.
51. Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P. Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome. Pediatr Infect Dis J 2008, 27(12):1089-1094. 10.1097/INF.0b013e31817fd423, 19008771.
52. Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, Mygland A. Oral doxycycline versus intravenous Ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 2008, 7(8):690-695. 10.1016/S1474-4422(08)70119-4, 18567539.
53. Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010, 17(1):8-16. 10.1111/j.1468-1331.2009.02862.x, 19930447.
54. Borg R, Dotevall L, Hagberg L, Maraspin V, Lotric-Furlan S, Cimperman J, Strle F. Intravenous Ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 2005, 37(6-7):449-454.
55. Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP, Krupp L, Gronseth G, Bever CT. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007, 69(1):91-102. 10.1212/01.wnl.0000265517.66976.28, 17522387.
56. Dotevall L, Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. Antimicrob Agents Chemother 1989, 33(7):1078-1080. 10.1128/AAC.33.7.1078, 176065, 2782858.
57. Karlsson M, Hammers S, Nilsson-Ehle I, Malmborg AS, Wretlind B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother 1996, 40(5):1104-1107. 163273, 8723448.
58. Ljostad U, Mygland A. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol 2010, 17(1):118-123. 10.1111/j.1468-1331.2009.02756.x, 19645771.
59. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, Kristoferitsch W, O'Connell S, Ornstein K, Strle F, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011, 17(1):69-79. 10.1111/j.1469-0691.2010.03175.x, 20132258.
60. Marques A. Chronic Lyme disease: a review. Infect Dis Clin North Am 2008, 22(2):341-360. 10.1016/j.idc.2007.12.011, 2430045, 18452806.
61. Eikeland R, Mygland A, Herlofson K, Ljostad U. European neuroborreliosis: quality of life 30 months after treatment. Acta Neurol Scand 2011, 124(5):349-354.
62. Takeshita S, Ono Y, Kozuma K, Suzuki M, Kawamura Y, Yokoyama N, Furukawa T, Isshiki T. Modulation of oxidative burst of neutrophils by doxycycline in patients with acute myocardial infarction. J Antimicrob Chemother 2002, 49(2):411-413. 10.1093/jac/49.2.411, 11815591.
63. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009, 119(16):2209-2216. 10.1161/CIRCULATIONAHA.108.806505, 19364980.